Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.1K

Management of HBV and HBV/HDV-Associated Liver Cirrhosis

Christoph Höner Zu Siederdissen1, Markus Cornberg1

  • 1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hanover, Germany.

Visceral Medicine
|July 15, 2016
PubMed

Insights

Early treatment of chronic hepatitis B (HBV) and hepatitis D (HDV) prevents cirrhosis complications. While nucleos(t)ide analogues suppress HBV DNA, new treatments are needed for HDV.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Chronic hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection are major causes of liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC).
  • Effective management strategies are crucial to prevent severe liver disease progression.

Purpose of the Study:

  • To review current management strategies for HBV mono-infection and HBV/HDV co-infection.
  • To emphasize treatment approaches for patients with liver cirrhosis.

Main Methods:

  • Literature review of current knowledge on HBV and HBV/HDV management.
  • Focus on treatment options and outcomes in liver cirrhosis.

Main Results:

  • Hepatitis B treatments include pegylated interferon (PEG-IFN) and nucleos(t)ide analogues (NUC).
  • PEG-IFN offers finite treatment for HBsAg loss in compensated cirrhosis, though rarely achieved.
  • NUCs suppress HBV DNA, requiring long-term therapy, potentially reversing cirrhosis, improving function, and reducing HCC risk.
  • Hepatitis D treatment is limited to PEG-IFN, which reduces disease progression but has high relapse rates; novel therapies are needed.

Conclusions:

  • Early intervention for chronic hepatitis B and D is vital to prevent cirrhosis complications.
  • Hepatocellular carcinoma surveillance is essential for patients with cirrhosis.
Abstract

Keywords:
HCCHepatitis BHepatitis DHepatocellular carcinomaLiver cirrhosisNucleos(t)ide analoguesPegylated interferon

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
730
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
315
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
984
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
461